The Claim
Plasma p-tau217 levels measured by the DiSMS and LyMedivh™ AXL assays are strongly correlated (r > 0.7) with plasma p-tau217 levels measured by the ALZpath Simoa assay, indicating that the novel assays detect the same biological signal as the reference assay.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Two new blood tests for p-tau217, called DiSMS and LyMedivh™ AXL, produce results that match the established ALZpath Simoa assay with high consistency, showing they measure the same protein marker in blood.
See the scientific wording
Plasma p-tau217 levels measured by the DiSMS and LyMedivh™ AXL assays show strong correlation (r > 0.7) with the reference ALZpath Simoa assay, indicating that these novel methods reliably measure the same biological signal despite different technical platforms.
A specific form of tau protein in the blood, marked by a phosphate group at position 217, exists in a fixed shape and quantity that different tests can detect reliably, no matter how the test is built.
What the research says
1 studyTwo new blood tests for Alzheimer’s disease give results that match the best existing test very closely — they catch nearly all cases and rarely make mistakes, meaning they’re measuring the same thing accurately, just using different methods.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.